Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor

Placenta

Volumn 36, Issue 2, 2015, Pages 121-124

  Yinon, Y ^a   Ben Meir, E ^a   Margolis, L ^a   Lipitz, S ^a   Schiff, E ^a   Mazaki Tovi, S ^a   Simchen, M J ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Angiogenic factors; Low molecular weight heparin; PLGF; sEng; sFlt 1

Indexed keywords

ENDOGLIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; LOW MOLECULAR WEIGHT HEPARIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; PLACENTA PROTEIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MATERNAL PLASMA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STORAGE TEMPERATURE; THIRD TRIMESTER PREGNANCY; THROMBOEMBOLISM; THROMBOPHILIA; ADULT; BLOOD; CASE CONTROL STUDY; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY COMPLICATIONS, HEMATOLOGIC; UPREGULATION;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LONGITUDINAL STUDIES; PLACENTA DISEASES; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY PROTEINS; UP-REGULATION;

EID: 84920872036     PISSN: 01434004     EISSN: 15323102     Source Type: Journal    
DOI: 10.1016/j.placenta.2014.12.008     Document Type: Article

References (27)

1. Bulletins-Obstetrics ACoP ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002 Obstet Gynecol 99 2002 159 167
2. C.J. Berg, A.P. Mackay, C. Qin, and W.M. Callaghan Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005 Obstet Gynecol 113 2009 1075 1081
3. A.P. MacKay, C.J. Berg, and H.K. Atrash Pregnancy-related mortality from preeclampsia and eclampsia Obstet Gynecol 97 2001 533 538
4. R.J. Levine, C. Lam, C. Qian, K.F. Yu, S.E. Maynard, and B.P. Sachs Soluble endoglin and other circulating antiangiogenic factors in preeclampsia N Engl J Med 355 2006 992 1005
5. R.J. Levine, S.E. Maynard, C. Qian, K.H. Lim, L.J. England, and K.F. Yu Circulating angiogenic factors and the risk of preeclampsia N Engl J Med 350 2004 672 683
6. S.E. Maynard, J.Y. Min, J. Merchan, K.H. Lim, J. Li, and S. Mondal Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 2003 649 658
7. S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto, and Y.M. Kim Soluble endoglin contributes to the pathogenesis of preeclampsia Nat Med 12 2006 642 649
8. T. Chaiworapongsa, R. Romero, J. Espinoza, E. Bujold, Y. Mee Kim, and L.F. Goncalves Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award Am J Obstet Gynecol 190 2004 1541 1547 discussion 1547-50
9. G.C. McKeeman, J.E. Ardill, C.M. Caldwell, A.J. Hunter, and N. McClure Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop Am J Obstet Gynecol 191 2004 1240 1246
10. R. Thadhani, W.P. Mutter, M. Wolf, R.J. Levine, R.N. Taylor, and V.P. Sukhatme First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia J Clin Endocrinol Metab 89 2004 770 775
11. A. Wang, S. Rana, and S.A. Karumanchi Preeclampsia: the role of angiogenic factors in its pathogenesis Physiol - Bethesda 24 2009 147 158
12. H.A. Mousa, and Z. Alfirevic Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 15 2000 1830 1833
13. M. Kupferminc, E. Rimon, A. Many, S. Maslovitz, J.B. Lessing, and R. Gamzu Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia Blood Coagul Fibrinolysis 22 2011 123 126
14. E. Rey, P. Garneau, M. David, R. Gauthier, L. Leduc, and N. Michon Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial J Thromb Haemost 7 2009 58 64
15. D. Baczyk, C. Dunk, B. Huppertz, C. Maxwell, F. Reister, and D. Giannoulias Bi-potential behaviour of cytotrophoblasts in first trimester chorionic villi Placenta 27 2006 367 374
16. P. Bose, S. Black, M. Kadyrov, C. Bartz, A. Shlebak, and L. Regan Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro Am J Obstet Gynecol 191 2004 2125 2131
17. S. Drewlo, K. Levytska, M. Sobel, D. Baczyk, S.J. Lye, and J. Kingdom Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling J Thromb Haemost 9 2011 2486 2497
18. V.A. Rosenberg, I.A. Buhimschi, C.J. Lockwood, M.J. Paidas, A.T. Dulay, and W. Ramma Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy Circulation 124 2011 2543 2553
19. M.A. Brown, M.D. Lindheimer, M. de Swiet, A. Van Assche, and J.M. Moutquin The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP) Hypertens Pregnancy 20 2001 IX-XIV
20. J.M. Dodd, A. McLeod, R.C. Windrim, and J. Kingdom Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction Cochrane Database Syst Rev 7 2013 CD006780
21. J.C. Gris, C. Chauleur, J.L. Faillie, G. Baer, P. Mares, and P. Fabbro-Peray Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial Thromb Haemost 104 2010 771 779
22. S. Sela, S. Natanson-Yaron, E. Zcharia, I. Vlodavsky, S. Yagel, and E. Keshet Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase Circ Res 108 2011 1063 1070
23. A. Rajakumar, R.W. Powers, C.A. Hubel, E. Shibata, F. von Versen-Hoynck, and D. Plymire Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women Placenta 30 2009 25 34
24. C.P. Thomas, J.I. Andrews, and K.Z. Liu Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta FASEB J 21 2007 3885 3895
25. S. Sela, A. Itin, S. Natanson-Yaron, C. Greenfield, D. Goldman-Wohl, and S. Yagel A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia Circ Res 102 2008 1566 1574
26. T.A. Moore Simas, S.L. Crawford, M.J. Solitro, S.C. Frost, B.A. Meyer, and S.E. Maynard Angiogenic factors for the prediction of preeclampsia in high-risk women Am J Obstet Gynecol 197 2007 244 e241-8
27. M.L. Sobel, J. Kingdom, and S. Drewlo Angiogenic response of placental villi to heparin Obstet Gynecol 117 2011 1375 1383